REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2017

Jan 4, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2017-01-03

Reporting Person: SING GEORGE L (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-01-03	Common Stock	M	7000	$19.69	Acquired	119772	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-01-03	Non-Qualified Stock Option (right to buy)	$19.69	M	7000	Disposed	2017-01-03	Common Stock (7000)	Direct
2017-01-03	Non-Qualified Stock Option (right to buy)	$376.69	A	7830	Acquired	2027-01-03	Common Stock (7830)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	3000	Indirect
Common Stock	4500	Indirect
Common Stock	10000	Indirect

Footnotes

F1: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.